According to a Wall Street Journal report, Sovaldi, a newly approved drug to treat Hepatitis C, could see between $5 billion and $9 billion in sales during its first year on the market, one of the largest sales for a new drug's first year.
Read the full report on Becker's Hospital Review.
Read the full report on Becker's Hospital Review.